Cargando…

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

INTRODUCTION: The aim of the present study was to evaluate the effect of 18‐week monotherapy with imeglimin on glucose tolerance and on insulin secretion/sensitivity in type 2 diabetic (T2D) patients. METHODS: The study was an 18‐week, double‐blind clinical trial in T2D subjects previously treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659655/ https://www.ncbi.nlm.nih.gov/pubmed/36239048 http://dx.doi.org/10.1002/edm2.371

Ejemplares similares

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
por: Fouqueray, Pascale, et al.
Publicado: (2021)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
por: Reilhac, Caroline, et al.
Publicado: (2022)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
por: Tomita, Yoshiko, et al.
Publicado: (2022)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
por: Gluais‐Dagorn, Pascale, et al.
Publicado: (2021)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy
por: Monternier, Pierre‐Axel, et al.
Publicado: (2022)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

Hypercalcemia and CYP24A1 Gene Mutation Diagnosed in the 2(nd) Trimester of a Twin Pregnancy: A Case Report
por: Romašovs, Andris, et al.
Publicado: (2021)

Insulin Infusion During Normoglycemia Modulates Insulin Secretion According to Whole-Body Insulin Sensitivity
por: Anderwald, Christian, et al.
Publicado: (2011)

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
por: Uchida, Taisuke, et al.
Publicado: (2023)

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Adequately Adapted Insulin Secretion and Decreased Hepatic Insulin Extraction Cause Elevated Insulin Concentrations in Insulin Resistant Non-Diabetic Adrenal Incidentaloma Patients
por: Anderwald, Christian-Heinz, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice
por: Pacini, Giovanni, et al.
Publicado: (2017)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

A Response to Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Uchida, Taisuke, et al.
Publicado: (2023)

Reproducibility and discrimination of different indices of insulin sensitivity and insulin secretion
por: Hudak, Sarah, et al.
Publicado: (2021)

Osteocalcin Is Related to Enhanced Insulin Secretion in Gestational Diabetes Mellitus
por: Winhofer, Yvonne, et al.
Publicado: (2010)

Association between a rare SNP in the second intron of human Agouti related protein gene and increased BMI
por: Kalnina, Ineta, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2lagea2atau5fm2pn00uhl30er